BORAY — Bora Pharmaceuticals Co., Ltd./ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2097461 ·
Last close
$2.30
Market Cap
$293.37M
52W High
$7.00
52W Low
$2.30
ADV30
17
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 6,452,777,000 | 2,528,855,000 | 1,089,530,000 | 611,935,000 | 53,868,591,000 | 5,594,525,000 | 35,640,478,000 |
| Jun 2026 | 5,889,454,000 | 2,430,225,000 | 986,641,000 | 555,763,000 | 52,077,131,000 | 8,431,018,000 | 34,541,633,000 |
| Mar 2026 | 4,001,231,000 | 1,442,628,000 | 408,606,000 | 25,838,000 | 45,331,756,000 | 4,832,012,000 | 28,703,088,000 |
| Dec 2025 | 4,860,654,000 | 1,772,261,000 | 557,571,000 | 331,759,000 | 44,714,187,000 | 5,076,889,000 | 27,241,998,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$3,123,455,000
Investing CF
$-3,480,558,000
Financing CF
$3,927,234,000
CapEx
$-1,160,714,000
Dividends Paid
$0
Buybacks
$-76,207,000
EPS Diluted TTM
$14.31
As of
2026-10-08
Balance + Analyst (yfinance extras)
Retained Earnings
$6,172,689,000
Inventory
$4,184,197,000
Receivables
—
ST Investments
$58,810,000
EBIT TTM
$3,224,530,000
Pretax Income TTM
$2,739,348,000
Interest Exp TTM
$485,182,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$19,557,484,544
EBITDA
$3,973,967,104
Free Cash Flow
$1,568,535,040
Enterprise Value
$17,423,044,608
Total Cash
$8,487,909,888
Total Debt
$21,815,470,080
Shares Out
127,552,019
Trailing EPS
$0.41
Book Value
$0.75
ROE
12.0%
ROA
4.0%
Div Yield
2.38%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 19,014,169,000 | 3,295,289,000 | 2,981,311,000 | 44,714,187,000 | 27,241,998,000 | 15,381,399,000 | 4,503,589,000 |
| Dec 2024 | 17,426,624,000 | 3,708,000,000 | 3,852,515,000 | 45,509,645,000 | 30,586,316,000 | 12,779,166,000 | 980,024,000 |
| Dec 2023 | 14,200,068,000 | 5,249,139,000 | 3,030,142,000 | 25,134,173,000 | 13,368,362,000 | 9,084,787,000 | 4,613,657,000 |
| Dec 2022 | 10,494,470,000 | 1,922,176,000 | 1,391,916,000 | 22,761,215,000 | 17,620,759,000 | 4,528,322,000 | 2,010,074,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ASG | LIBERTY ALL STAR GROWTH FUND INC. | $293.10M | $4.60 | — |
| PPHC | Public Policy Holding Company, Inc. | $294.75M | $9.64 | — |
| CION | CION Investment Corp | $291.77M | $5.93 | — |
| FLXS | FLEXSTEEL INDUSTRIES INC | $295.71M | $71.05 | — |
| BGT | BLACKROCK FLOATING RATE INCOME TRUST | $295.86M | $9.92 | — |
News headlines (Yahoo Finance, 1h cache)
UPSHER-SMITH LAUNCHES TWO STRENGTHS OF BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION
2026-11-09 15:51 · Yahoo
Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets
2026-07-23 12:15 · Yahoo
Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations
2026-07-02 15:00 · Yahoo
UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)
2026-05-20 14:00 · Yahoo
NTN (TSE:6472) Stock May Be 43% Undervalued Based On Cash Flow
2026-10-26 19:11 · Yahoo
UPSHER-SMITH LAUNCHES FLUVOXAMINE MALEATE EXTENDED-RELEASE CAPSULES
2026-09-30 16:45 · Yahoo
UPSHER-SMITH EXPANDS PORTFOLIO WITH LAUNCH OF GLATIRAMER ACETATE INJECTION
2026-08-20 14:00 · Yahoo
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
2026-07-15 00:00 · Yahoo
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
2026-07-02 13:25 · Yahoo
GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)
2026-05-12 15:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.